Pontus KjellmanResearch Engineer
Research areas and keywords
UKÄ subject classification
- Cancer and Oncology
- Medical Biotechnology
- Radiology, Nuclear Medicine and Medical Imaging
- Nano Technology
Prostate cancer is the most prevalent form of cancer among men, with approximately 9000 confirmed cases each year in Sweden. There is currently no diagnostic test that can reliably distinguish between aggressive and indolent disease at an early stage and the methods for detecting metastatic growth are blunt and indirect. Our work in this project intends to develop a new agent that with high sensitivity and accuracy delivers diagnostics and/or therapeutics to its target tissue. Antibodies targeted towards human kallikreins are coupled to superparamagnetic iron oxide nanoparticles which can be further modified to suite the intended use (e.g. detection or therapy). The nanoparticles are designed to be multimodal, meaning that they have multiple abilities depending on what molecules are conjugated to their surface. Coupling of antibodies (or parts thereof) to the nanoparticles gives them the ability to target a certain tissue, radioactive isotopes gives them the abillity to be detected with medical imaging cameras such as PET and SPECT and to deliver therapeutic doses to malignant growths.
In another project we are investigating the use of a novel antibody for detection and therapy of different forms of leukemia. The antibodies are targeted towards the cancer antigen Preferentially Expressed Antigen in Melanoma (PRAME) which has been shown to be overexpressed in numerous forms of cancer while only occuring at low levels in healthy tissue. Here we use PRAME-specific antibodies labeled with radioactive isotopes for detection and therapy studies.
Recent research outputs
Research output: Contribution to journal › Article
Research output: Chapter in Book/Report/Conference proceeding › Paper in conference proceeding